会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 101. 发明公开
    • 아폽토시스 유도제
    • 疫苗诱导剂
    • KR1020000053108A
    • 2000-08-25
    • KR1019997004032
    • 1997-10-31
    • 다카라 바이오 가부시키가이샤
    • 사카이다케시유푸공고야마노부토타츠미요코사가와히로아키이카이가츠시게가토이쿠노신
    • A61K31/70A61P35/00
    • A61K36/82A23L33/105A23V2002/00A61K31/00A61K36/02A61K36/07A61K36/899A23V2200/308A23V2250/208
    • PURPOSE: A highly-safe extracted fraction derived from plants, microorganisms or animals having an apoptosis inducing action and to offer an apoptosis inducing agent and an anticancer agent containing the fraction, a functional food or beverage containing the fraction as a constituting component and a method for manufacturing them are provided. CONSTITUTION: A apoptosis inducing agent is made into a pharmaceutical preparation by combining the glycerolipid and/or glyceroglycolipid such as those/that derived from plants, microorganisms or animals which are/is effective component(s) with a known pharmaceutical carrier. Generally, the apoptosis inducing compound(s) such as glycerolipid and/or glyceroglycolipid are/is compounded with a pharmaceutically acceptable liquid or solid carrier followed, if necessary, by adding solvent, dispersing agent, emulsifier, buffer, stabilizer, vehicle, binder, disintegrating agent, lubricant, etc. thereto whereupon a solid preparation such as tablets, granules, diluted powder, pulverized preparation and capsules and liquid preparation such as normal liquid preparation, suspension and emulsion can be prepared. Alternatively, the compound(s) may be made into a dry preparation which can be converted into liquid by addition of a suitable carrier thereto before actual use.
    • 目的:从具有细胞凋亡诱导作用的植物,微生物或动物得到的高度安全的提取部分,提供细胞凋亡诱导剂和含有该级分的功能食品或饮料,含有该部分作为构成成分的功能性食品或饮料 提供制造它们。 构成:通过将甘油脂和/或甘油糖脂例如那些来自植物,微生物或动物的那些/有效成分与已知的药物载体组合而制成的细胞凋亡诱导剂。 通常,将凋亡诱导化合物如甘油脂和/或甘油糖脂与药学上可接受的液体或固体载体混合,如果需要,通过加入溶剂,分散剂,乳化剂,缓冲剂,稳定剂,载体,粘合剂, 崩解剂,润滑剂等,由此可以制备片剂,颗粒剂,稀释粉末,粉碎制剂和胶囊等固体制剂和液体制剂如正常液体制剂,悬浮液和乳液。 或者,化合物可以制成干制剂,其可以在实际使用之前通过加入合适的载体而转化成液体。
    • 102. 发明公开
    • 신규 아미노말단 보호기 유리 효소
    • 新型氨基酸终止酶
    • KR1020000022114A
    • 2000-04-25
    • KR1019980710524
    • 1997-06-19
    • 다카라 바이오 가부시키가이샤
    • 이즈유끼꼬다나까데쓰끼미야기마사루다니가와데쓰오도모노준쓰나사와스스무가또이꾸노신
    • C12N15/57C12N9/48C07K16/40C12Q1/68
    • C12N9/48
    • PURPOSE: Provided is an amino terminal protecting group-releasing enzyme characterized in that the enzyme possesses an activity for releasing a protecting group by acting on a peptide of which amino terminal is blocked by the protecting group (hereinafter abbreviated as a term "amino terminal protecting group-releasing activity"), and exhibits said activity for two or more protecting groups CONSTITUTION: Provided is an amino terminal protecting group-releasing enzyme characterized in that the enzyme possesses an activity for releasing a protecting group by acting on a peptide of which amino terminal is blocked by the protecting group, and exhibits the activity for two or more protecting groups, or a functional equivalent thereof; a DNA encoding the same; a method for producing the enzyme; a method for removing amino terminal protecting group including the step of subjecting to a reaction with the enzyme to release amino terminal protecting group; and a method for analyzing an amino acid sequence. The above enzyme is useful in the analysis of an amino acid sequence of peptides, particularly proteins and peptides, of which amino terminal is blocked by unknown protecting groups
    • 目的:提供一种氨基末端保护基释放酶,其特征在于该酶具有通过作用于氨基末端被保护基团阻断的肽(以下简称为术语“氨基末端保护基”)释放保护基的活性 组释放活性“),并且表现出对两个或更多个保护基团的所述活性构成:提供了一种氨基末端保护基团释放酶,其特征在于该酶具有释放保护基团的活性, 末端被保护基团封闭,并表现出两个或更多个保护基或其功能等同物的活性; 编码该DNA的DNA; 一种生产该酶的方法; 一种除去氨基末端保护基的方法,包括与酶反应释放氨基末端保护基的步骤; 以及分析氨基酸序列的方法。 上述酶可用于分析肽,特别是蛋白质和肽的氨基酸序列,其氨基末端被未知保护基团阻断
    • 103. 发明公开
    • 세포조성물
    • 细胞组成
    • KR1020000010744A
    • 2000-02-25
    • KR1019980708857
    • 1997-06-30
    • 다카라 바이오 가부시키가이샤
    • 아사다키요조고니시하루코고야마노부토가토이쿠노신
    • C12N5/00
    • C12N5/0093C12N5/0647C12N2501/125C12N2501/23C12N2501/90
    • PURPOSE: A hematopoietic stem cell composition from which cancer cells have been eliminated is provided for the stable delivery of gene not to cancer cells but to target normal cells. CONSTITUTION: The cell composition comprises hematopoietic stem cells from which cancer cells have been practically eliminated by using apoptosis inducers specific to the cancer cells; and optionally a foreign gene delivered into the hematopoietic stem cells. The apoptosis inducers is a sulfated polysaccharide such as fucoidan and dextran sulfate and/or degraded produces thereof; or uronic acid, its derivatives and/or degraded product thereof; and 4,5-dihydroxy-2-cyclopenten-1-one. Fucoidan may be prepared Fucus evannescens, Kjellmaniella crassifolia, Laminaria japonica, Undaria pinnatifida, Stichous japonicus and Holothuria lecospilota. Fucoidan U prepared comprises mainly fucose, man nose and galactose, contains uronic acid, and is degraded by fucoidanase produced from Flavobacterium sp. SA-0082 (FERM BP-5402). Fucoidan F prepared comprises mainly fucose, does not contain uronic acid, and does not degraded by fucoidanase produced from Flavobacterium sp. SA-0082 (FERM BP-5402).
    • 目的:提供癌细胞已经被去除的造血干细胞组合物,用于稳定递送基因不是癌细胞,而是靶向正常细胞。 构成:细胞组成包括造血干细胞,通过使用对癌细胞特异性的细胞凋亡诱导剂,癌细胞已被实际消除; 以及任选地将外源基因递送至造血干细胞。 凋亡诱导剂是硫酸化多糖如岩藻多糖和硫酸葡聚糖和/或其降解产物; 或糖醛酸,其衍生物和/或其降解产物; 和4,5-二羟基-2-环戊烯-1-酮。 岩藻依聚糖可以被制备为Fucus evannescens,Kjellmaniella crassifolia,Laminaria japonica,Undaria pinnatifida,Stichous japonicus和Holothuria lecospilota。 制备的岩藻依聚糖U主要包含岩藻糖,人鼻和半乳糖,含有糖醛酸,并由黄杆菌属产生的岩藻多糖酶降解。 SA-0082(FERM BP-5402)。 制备的岩藻依聚糖F主要包含岩藻糖,不含糖醛酸,并且不被由黄杆菌属产生的岩藻依聚糖酶降解。 SA-0082(FERM BP-5402)。